Company: MDCXW
Filing Date: 2025-11-19
Form Type: S-1
Source: 0001062993-25-016962
Chunk: 8

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-19
Form: S-1
Chunk 8
---
 For example, in August 2025, we acquired 98.6% of the issued and outstanding shares of Antev Limited ("Antev"), a UK-based late clinical-stage drug development company which is developing Teverelix.

<div align='center'>1</div>

For additional information regarding the business of the Company and the regulatory environment in which it operates, please refer to the prospectus under the heading "Our Business."

Our Strengths

Our key competitive strengths include:

A senior management team, led by Dr. Raza Bokhari, that has deep experience in medicine and pharmaceutical science as well as a proven track record in business development and entrepreneurship.

Successful completion of a Phase 1 study of SkinJect.

Potential to treat a range of other common non-melanoma skin cancers as well as pre-cancerous lesions.

Summary Risk Factors

Investing in our securities involves risk. Our ability to execute our strategy is also subject to certain risks. The risks described in "Risk Factors" in this prospectus may cause us to not realize the full benefits of our strengths or may cause us to be unable to successfully execute all or part of our strategy. Some of the more significant risks include the following:

our financial results, including our ability to generate earnings and achieve and sustain profitability (as of September 30, 2025, we had an accumulated deficit of approximately $56.2 million, which was comprised of approximately $12.4 million of accumulated deficit of SkinJect as of September 30, 2023, the day after it became a subsidiary of the Company, and approximately $43.8 million of deficit accumulated by the Company on a consolidated basis), may vary significantly from forecasts and from period to period;

the progress, timing and completion of our research, development and preclinical studies and clinical trials for our products and product candidates

we may not successfully integrate Antev into our business and operations or successfully develop Teverelix;

our ability to market, commercialize, achieve market acceptance for and sell our products and product candidates, our ability to develop, manage and maintain our direct sales and marketing organizations;

our ability to continue as a going concern and if we are unable to obtain additional financing from outside sources and/or eventually generate enough revenues, we may be forced to curtail or discontinue our operations;

our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing;

market risks regarding consolidation in the healthcare, pharmaceutical and biotech/life sciences industry;

the willingness of healthcare providers to